🇺🇸 FDA

Intelligence · Clinical Pipeline

Phase II Pipeline Programs

Proof-of-concept and dose-finding clinical programs in Phase II development.

Programs
7,238

Quick answer

NovaPharmaNews tracks 7,238 phase ii pharmaceutical pipeline programs from ClinicalTrials.gov. Proof-of-concept and dose-finding clinical programs in Phase II development.

Top sponsors

Page 6 of 151

  1. ABEMACICLIB , RO7197597

    Fondazione Telethon ETS

    ER-positive, HER2-negative Early breast cancer

    phase 2 small molecule active

    1 trial

  2. ABI-H0731

    ASSEMBLY BIOSCIENCES, INC.

    Chronic Hepatitis B

    phase 2 small molecule terminated

    6 trials

  3. ABIRATERONE, DAROLUTAMIDE, DZR123, -, -, ABIRATERONE, DZR123, DAROLUTAMIDE

    Novartis Pharmaceuticals

    Metastatic hormone-sensitive prostate cancer

    phase 2 small molecule active

    1 trial

  4. ABO-102

    ABEONA THERAPEUTICS INC.

    MPS IIIA

    phase 2 small molecule terminated

    1 trial

  5. ABO-102, ABO-102, ABO-102

    Lacuna Pharma Pty Ltd

    Mucopolysaccharidosis type IIIA

    phase 2 small molecule active

    1 trial

  6. ABP-450

    AEON Biopharma

    Migraine

    phase 2 small molecule terminated

    2 trials

  7. ABP-450

    AEON Biopharma

    Cervical Dystonia

    phase 2 small molecule completed

    2 trials

  8. ABTL0812, IRINOTECAN, TEMOZOLOMIDE

    The George Institute

    Relapsed/refractory neuroblastoma and other solid tumours

    phase 2 small molecule active

    1 trial

  9. AC102-Suspension 12 mg/ml, placebo gel, Placebo matching Prednisolone, Prednisolon 10 mg GALEN®

    Lacuna Pharma Pty Ltd

    Idiopathic Sudden Sensorineural Hearing Loss

    phase 2 small molecule active

    1 trial

  10. ACE-536

    Celgene Europe Limited

    Beta-Thalassemia

    phase 2 small molecule active

    1 trial

  11. ACE393

    Fulcrum Therapeutics

    Campylobacter Infection

    phase 2 mab active

    1 trial

  12. ACETYLCYSTEINE , DEXAMETHASONE , DIPHENHYDRAMINE , GLUCOSE

    Inhibrx Biosciences

    Unresectable or metastatic conventional chondrosarcoma

    phase 2 small molecule active

    1 trial

  13. ACP-044 Dose A

    Acadia Pharmaceuticals B.V.

    Acute Postoperative Pain

    phase 2 small molecule completed

    1 trial

  14. ACP-044 Dose A

    Acadia Pharmaceuticals B.V.

    Osteoarthritis Pain

    phase 2 small molecule terminated

    1 trial

  15. ACP-103

    Acadia Pharmaceuticals B.V.

    Hallucinations

    phase 2 small molecule completed

    1 trial

  16. ACP-103

    Acadia Pharmaceuticals B.V.

    Schizophrenia

    phase 2 small molecule completed

    1 trial

  17. ACP-104

    Acadia Pharmaceuticals B.V.

    Schizophrenia

    phase 2 small molecule completed

    2 trials

  18. ACP-211

    Acadia Pharmaceuticals B.V.

    Major Depressive Disorder (MDD)

    phase 2 small molecule active

    1 trial

  19. ACR-368

    Acrivon Therapeutics

    Endometrial Adenocarcinoma

    phase 2 small molecule active

    1 trial

  20. ACR16

    Teva Pharma GmbH

    Huntington Disease

    phase 2 small molecule completed

    1 trial

  21. ACT-1004-1239 matching placebo

    Lacuna Pharma Pty Ltd

    Progressive multiple sclerosis (MS)

    phase 2 small molecule active

    1 trial

  22. ACT-20-MSC

    Aspire Biopharma Holdings

    COVID-19 Pneumonia

    phase 2 mab active

    1 trial

  23. ACTIQ (Oral Transmucosal Fentanyl Citrate [OTFC])

    Teva Pharma GmbH

    Pain

    phase 2 small molecule completed

    1 trial

  24. ACTIQ®

    Teva Pharma GmbH

    Cancer

    phase 2 small molecule completed

    1 trial

  25. ADALIMUMAB, USTEKINUMAB , ADALIMUMAB , USTEKINUMAB, Olumiant 4 mg film-coated tablets

    Pari Pharma GmbH

    Folliculitis decalvans

    phase 2 small molecule active

    1 trial

  26. ADCETRIS 50 mg powder for concentrate for solution for infusion

    Takeda

    Hodgkin lymphoma (HL) - Hodgkin lymphoma (HL), a neoplasm of lymphoid tissue which is histopathologically defined by the presence of malignant Hodgkin Reed-Sternberg (HRS) cells in a background of inflammatory cells. The proposed pediatric study has been designed to evaluate brentuximab vedotin as a component of a multiagent frontline chemotherapy regimen in patients with advanced stage, newly diagnosed HL, here defined as Stage III and Stage IV and a ≥50 Lansky Play-Performance or Karnofsky Performance Status.

    phase 2 small molecule active

    1 trial

  27. ADCETRIS 50 mg powder for concentrate for solution for infusion, DACARBAZINE , DOXORUBICIN , DEXAMETHASONE , VINBLASTINE , CYCLOPHOSPHAMIDE , ETOPOSIDE

    Ningbo Cancer Hospital

    Advanced stage Hodgkin Lymphoma

    phase 2 small molecule active

    1 trial

  28. ADCT-301

    ADC Therapeutics SA

    Acute Myeloid Leukemia (AML)

    phase 2 small molecule terminated

    1 trial

  29. ADCT-602

    ADC Therapeutics SA

    Blasts 5 Percent or More of Bone Marrow Nucleated Cells

    phase 2 mab terminated

    1 trial

  30. ADENOVIRUS/PSA VACCINE

    United Therapeutics Europe Ltd

    Hormone Refractory Prostate Cancer

    phase 2 mab completed

    1 trial

  31. ADMSC-fib safety and efficacy in patients with chronico wounds

    The George Institute

    chronic wounds

    phase 2 other active

    1 trial

  32. ADSC01

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Connective Tissue Diseases

    phase 2 mab active

    1 trial

  33. ADSTILADRIN

    Ferring Pharmaceuticals

    Low-grade upper track urothelial carcinoma (LG-UTUC)

    phase 2 small molecule active

    1 trial

  34. ADX-038

    Lacuna Pharma Pty Ltd

    Complement-Mediated Kidney Disease

    phase 2 small molecule active

    1 trial

  35. ADX-038, Sodio cloruro Galenica Senese 0,9% solvente per uso parenterale

    Lacuna Pharma Pty Ltd

    Geographic atrophy secondary to age-related macular degeneration

    phase 2 small molecule active

    1 trial

  36. ADX-102 Ophthalmic Drops (0.5%)

    Aldeyra Therapeutics

    Conjunctivitis, Allergic

    phase 2 small molecule completed

    1 trial

  37. ADX-102 Ophthalmic Solution (0.5%)

    Aldeyra Therapeutics

    Dry Eye Syndromes

    phase 2 small molecule completed

    1 trial

  38. ADX-2191

    Aldeyra Therapeutics

    Retinitis Pigmentosa

    phase 2 small molecule completed

    1 trial

  39. ADX-629

    Aldeyra Therapeutics

    Nephrotic Syndrome

    phase 2 small molecule terminated

    1 trial

  40. ADX-629

    Aldeyra Therapeutics

    Atopic Asthma

    phase 2 small molecule completed

    1 trial

  41. ADX-629

    Aldeyra Therapeutics

    Alcohol Hepatitis

    phase 2 small molecule completed

    1 trial

  42. ADX-629

    Aldeyra Therapeutics

    Ethanol Intoxication

    phase 2 small molecule completed

    1 trial

  43. ADX-629

    Aldeyra Therapeutics

    Chronic Cough

    phase 2 small molecule completed

    1 trial

  44. ADX-629

    Aldeyra Therapeutics

    Plaque Psoriasis

    phase 2 small molecule completed

    1 trial

  45. ADX-629

    Aldeyra Therapeutics

    Covid19

    phase 2 small molecule completed

    1 trial

  46. ADX-629 (Open-label)

    Aldeyra Therapeutics

    Atopic Dermatitis

    phase 2 small molecule completed

    1 trial

  47. ADX-N05

    Jazz Pharmaceuticals Ireland Limited

    Narcolepsy

    phase 2 small molecule completed

    2 trials

  48. ADX10059

    Addex Therapeutics

    Migraine

    phase 2 small molecule terminated

    1 trial

Frequently asked questions

How many Phase II pipeline programs are in the directory?

7,238 published programs match this development stage in our ClinicalTrials.gov index.

What defines this pipeline stage?

Phase and status reflect ClinicalTrials.gov registry fields at last sync. See our clinical trial phases reference for methodology.

Data attribution: Data sources · All pipeline programs

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.